ETX 2514

Drug Profile

ETX 2514

Alternative Names: ETX2514

Latest Information Update: 10 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Developer Entasis Therapeutics
  • Class Antibacterials; Small molecules
  • Mechanism of Action Beta lactamase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acinetobacter infections
  • Preclinical Gram-negative infections

Most Recent Events

  • 07 Oct 2017 Adverse events data from a phase I trial in Acinetobacter infections (In volunteers) presented at the IDWeek 2017 (IDW-2017)
  • 07 Jun 2017 Entasis Therapeutics completes phase I trial in Acinetobacter infections (Combination therapy, In volunteers, Monotherapy) in Australia
  • 22 Apr 2017 Antimicrobial data from preclinical trials in Gram-negative infections presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top